Aspen Pharmacare Holdings Limited · JSE:APN
Aspen Pharmacare — Technical Presentation (November 2009)
31 slides from Aspen Pharmacare's technical presentation, Nov 6, 2009
Slide 1: Investors' site visit to Aspen's manufacturing headquarters in Port Elizabeth
Investors’ site visit to Aspen’s manufacturing headquarters in Port 06 Elizabeth November 2009 Presented by: Dr Morne Geyser, Head of Operations
Slide 2: Transformation of Aspen's manufacturing base
Transformation of Aspen’s manufacturing base General Facility has been on the present site for the last 65 years Acquired by Aspen from SAD in March 1999, together with facilities in EL and JHB Mainly supplied to the South African market Within 11 years, Aspen has transformed from a being a
Slide 3: An aerial view of the Port Elizabeth site
An aerial view of the Port Elizabeth site Technical centre UNIT 3:General Facility UNIT 2: OSD UNIT 1: Packing UNIT 1:OSD UNIT 1: Bottling Plant Steriles Facility: SVP SVP warehouse 3
Slide 4: Regulatory Authorities relevant to South African Operations
Regulatory Authorities relevant to South African Operations United States EU South Brazil FDA (MRHA) Africa REG AUTHORITY FDA MHRA WHO MCC/PICs ANVISA Aspen Unit 1 (OSD) X X X X X Aspen Unit 2 (OSD) X X Aspen Steriles (SVP) X X Aspen Unit 3 (Gen X Facility) Aspen East London X Aspen Distribution X X
Slide 5: Good Manufacturing Practice Controls (GMP)
Good Manufacturing Practice Controls (GMP) GMP Compliance Managem Model as implemented ent within Aspen in order Incident to comply with the managem Personnel ent atest International Requirements for Integrated Quality Systems Effective Replaces older Lab Quality Documenta “Rules based” GMP Controls
Slide 6: Aspen-Multinational Partnerships
Aspen-Multinational Partnerships Boehringe r Nevirapine Ingelheim Lamivudine, Zidovudine & GSK Others Stavudine, Didanosine, BMS Atazanavir Gilead Tenofovir & Emtricitabine MSD Efavirenz Iroko Aldomet and Indocid Cycloserine and Eli Lilly Capreomycin 6
Slide 7: Manufacturing Rationalisation Project
Manufacturing Rationalisation Project GENERAL FACILITY Complexity reduction End State : Specialised solids packing facility EAST UNIT 1 UNIT 2(a) UNIT 2(b) LONDON High volume domestic + Fluid Bed Oven dried Lennon Dutch export tablets Dried tablets tablets Medicines & & capsules & capsules (LDM) cap
Slide 8: Flow Diagram of the tabletting processes
Flow Diagram of the tabletting processes Air Dispensing Scale Sievin Fluidised g Bed Dryer Granulat Ai ion Magnesium r Blendi Stearate ng Sievin g Compress ion Packagi ng Coating / Capsule fill 8
Slide 9: Unit 1 - Oral Solid Dosage Facility
Unit 1 - Oral Solid Dosage Facility Established 2005 High-volume production of tablets and capsules with a strong focus on: Key, high-volume tender products ARV’s – supplied to State, private & export sectors Licensed products – GSK(ARV’s), Gilead (Truvada, Viread), Iroko (Aldomet, Indocid
Slide 10: Unit 1 - Capacity overview
Unit 1 - Capacity overview Unit 1 manufactures 2.4 billion tablets Investments were made during 2008 and 2009 to increase the capacity in the roller compaction, encapsulation and coating areas, amounting to R20 million. Capacities in each of these areas was doubled For an additional investment
Slide 11: Unit 2 – Oral Solid Dosage Facility
Unit 2 – Oral Solid Dosage Facility New solids manufacturing facility to replace bulk tablet manufacturing in the General Facility Value of investment is close to R300 million Small to medium volume solids production for sales into selected regulated markets, with strong focus on LATAM Use
Slide 12: An overview of the fluid-bed drying process
An overview of the fluid-bed drying process Using the older oven drying technology: Wet granule obtained during tablet manufacture is dried as a static bed of material spread on trays in an oven Process time is longer, requiring an average of 8 - 16 hour drying time The newer fluid bed dryin
Slide 13: Unit 3 – General Facility
Unit 3 – General Facility Unit 3 currently comprises the following: Large range of lower volume solids manufacturing and packing Large range of liquids and semi-solids (e.g. creams, ointments and suppositories) manufacturing and packing A phased process for the transfer of products to Unit 1
Slide 14: Sterile Facility (SVP)
Sterile Facility (SVP) Specialist facility for the manufacture of eye drops, lyophilised vials and sterile injectables The Facility will also produce hormonal vials and ampoules – a niche capability to supply female contraceptives and HRT products Project commenced in 2007, presenting challeng
Slide 15: Maintaining a Sterile Environment
Maintaining a Sterile Environment HVAC HEPA Filters LAF Canopy Plastic curtain HEPA Filters HEPA Filters Grade A Grade B Grade B Filling Room RAB Enclosed Filling Machine 15
Slide 16: SVP – Multi-Product Suite
SVP – Multi-Product Suite Lines 1 and 2: High volume eye drops with an annual capacity of about 50 million units 24 million units to be exported to US and Canada under a manufacturing contract with Prestige Brands Will introduce Aspen’s range of eye drops – Safyr Bleu, Eyegene, Oculerge Line 3
Slide 17: SVP–Hormonal Injectables
SVP–Hormonal Injectables Line 4: High volume ampoule filling capability for hormonal injectables - a niche capability which is very relevant to emerging markets Commercial production will commence during 2010 with the introduction of Bayer Nur-Isterate for South Africa Annual capacity for ampo
Slide 18: Aerial view of East London site
Aerial view of East London site Penicillin Plant Oral Contraceptives General Manufacture 18
Slide 19: East London multi-purpose site
East London multi-purpose site Currently highly flexible, small volume, niche, solids manufacture including high potency drugs To streamline production and focus on manufacturing synergy and cost savings Close to 1 billion tablets are being produced at East London, approximately 70% of which w
Slide 20: Focus on Continuous Improvement Initiatives
Focus on Continuous Improvement Initiatives Strategic initiatives: Rationalisation of capabilities between PE and EL facilities to optimise operational efficiencies and accommodate increasing demand To achieve economies of scale as volumes are scaled up upon completion of expansion projects To
Slide 21: Sustainability Initiatives
Sustainability Initiatives On-site clinics provide a wide range of health checks, HIV/AIDS counselling and employee support and healthcare awareness programmes Aspen, through QualSA, provides financial support to employees and their immediate families suffering from HIV/AIDS A SHE systems deve
Slide 22: Improvement in Recoveries
Improvement in Recoveries +78% +120% 2007 2008 2009 22
Slide 23: Our employees are invaluable to our business
Our employees are invaluable to our business and we have made an investment in initiatives to develop, nurture and retain our people to grow and sustain our manufacturing excellence.... 23
Slide 24: Human Resources Philosophy
Human Resources Philosophy The Group’s HR philosophy aims to promote the following: Acquisition of talent Positioning Aspen as an “employer of choice” Retention of talent Organisational transformation A talent pipeline for the future A strong leadership cadre A culture of accountabilit
Slide 25: Investing in people - Learning
Investing in people - Learning A significant investment has been made in learning and development of both operating and support staff in an attempt to: Increase the base of scarce skills which are critical to the business Empower production staff to operate new equipment using improved process
Slide 26: Investing in People - Organisational Development
Investing in People - Organisational Development In total 386 employees have undergone psychometric assessments, most of which were conducted for employees at the manufacturing operations Matches employees’ technical and behavioural competencies to the functional requirements of the job which ar
Slide 27: Pharmacist Assistant Graduates, CIMA Learnership Graduates
Pharmacist Assistant Graduates CIMA Learnership Graduates Accelerated Development Graduate: Godfrey Keele Pharmacist Interns: Simbongile Pambuka, Lance Geswindt & Bashir Ensoor 27
Slide 28: Prospects in manufacturing: Our Assets
Prospects in manufacturing We have built a world-class pharmaceutical manufacturing facility, based on a strong foundation of: A robust MANUFACTURING PROCESS to produce high-quality products OUR Experienced, ASSETS Sophisticated INFRASTRUCT competent and URE with committed diverse PEOPLE capabilit
Slide 29: Prospects in manufacturing (cont.)
Prospects in manufacturing(cont.) The investment made in expanding the hard asset base (infrastructure) has been supported by an investment in the soft assets including developing people and enhancing processes Our cost of manufacturing is competitive against both local and international peers
Slide 30: From humble beginnings, we have built world-class manufacturing capabilities
From humble beginnings, we have built world- class manufacturing capabilities and developed a professional and competent team to support Aspen’s transformation into a leading international generics pharmaceutical company, able to deliver in 2010 and beyond... 30
Slide 31: Investors' site visit to Aspen's manufacturing headquarters in Port Elizabeth
Investors’ site visit to Aspen’s manufacturing headquarters in Port 06 Elizabeth November 2009 Presented by: Dr Morne Geyser, Head of Operations
Aspen Pharmacare Holdings — Technical Presentation (November 2009) on 6ix